TORONTO, ONTARIO — (Marketwire) — 08/30/11 — BioExx Specialty Proteins Ltd. (TSX: BXI) is pleased to announce that Mr. Richard (Ric) Rumble has been appointed to its Board of Directors. The Company welcomes Mr. Rumble–s extensive scientific background and successful growth company experience, both domestically and internationally.
Mr. Rumble presently serves as the President and Chief Executive Officer of TSO(3)Inc. (TSX: TOS), an innovator in low temperature sterilization systems used in health care settings. Mr. Rumble has accumulated more than 25 years experience within the North American and global medical industry. During this time he has delivered significant and sustained revenue and earnings growth, led successful new commercial strategies, and negotiated and integrated large-scale acquisitions. Mr. Rumble holds a BSc in biology and an Honours BSc in microbiology and immunology from the University of Western Ontario. Prior positions held by Mr. Rumble include President of BERCHTOLD Corporation; Vice President, Sales & Marketing for Strategic Diagnostics Inc.; Vice President and General Manager of STERIS Corporation; and President and Chief Executive Officer of MediVators Inc. In addition, Mr. Rumble held a number of domestic and international management positions at 3M Company.
Plant Update
BioExx also advises that its various planned improvements and capital projects during plant shutdown have proceeded well and the team looks forward to re-start. The plant has been very active during this time, with a number of initiatives underway, all oriented towards enhancing forward performance. Previously planned re-start schedules have shifted slightly, in part due to difficulty in sourcing enough electricians during summer. Crush operations are re-starting today, final protein work and initial commissioning will be underway this week, with final commissioning, training, and preliminary protein operations occurring next week, and production resuming in a more regular fashion the following week. Once the Company has had a chance to run in the improved environment for a period of time, to achieve measurable and meaningfully reportable results, a further update on status will be provided.
About BioExx Specialty Proteins Ltd.
Headquartered in Toronto, Canada, BioExx is a technology and industrial processing company focused on the extraction of oil and high-value proteins from oilseeds for global food, beverage, nutrition, and other markets. BioExx employs trade secret, patented and patent-pending technologies that utilize significantly lower temperatures than conventional oilseed processing, in order to enable the improved separation of proteins from oilseeds. BioExx believes that these processes cumulatively have the potential to make a valuable contribution to global food and protein supply while maintaining an environmentally sustainable footprint. BioExx is commencing operation of a small commercial scale canola processing facility in Saskatoon, Saskatchewan, and has a mission to construct and operate and/or facilitate the development of additional and larger processing facilities on a global basis.
To find out more about BioExx Specialty Proteins Ltd. (TSX: BXI), please visit .
The statements made in this press release include forward-looking statements that involve a number of risks and uncertainties. These statements relate to future events or future performance and reflect management–s current expectations and assumptions. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements, such as the economy, generally, competition in its target markets, the demand for BioExx–s products, the availability of funding, the efficacy of its technology, and the anticipated costs of BioExx–s plant construction and operation. These forward-looking statements are made as of the date hereof and BioExx does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from BioExx–s expectations and projections.
Contacts:
BioExx Specialty Proteins Ltd.
Chris Schnarr
Chief Financial Officer
(416) 588-4442 x111
Investor Relations:
Brisco Capital Partners
Scott Koyich
President
(403) 262-9888